 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | SDC1 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.
It is the anti-CD138 chimerized MAb (nBT062) [1] linked to the maytansinoid DM4. [1]
It is being investigated as part of a treatment for multiple myeloma. [1]
Preliminary data has been reported in 2013 from an early stage clinical trial in combination with Lenalidomide and Dexamethasone. [1] Follow up data reported "encouraging efficacy" in December 2014. [2]
As of December 2014 [update] , it is in clinical trials for triple negative metastatic breast cancer and metastatic urinary bladder cancer. [2]
CD138 (Syndecan-1) is highly overexpressed on various solid tumors and in hematological malignancies, and represents one of the most specific target antigens for identification of multiple myeloma (MM) cells. [1] The antibody part binds to CD138 on the target cells and then the DM4 kills the cell.[ citation needed ]